Matthew B Laurens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9036035/publications.pdf

Version: 2024-02-01

70 papers 3,854 citations

236833 25 h-index 59 g-index

74 all docs

74 docs citations

times ranked

74

3528 citing authors

#	Article	IF	CITATIONS
1	An In Silico Analysis of Malaria Pre-Erythrocytic-Stage Antigens Interpreting Worldwide Genetic Data to Suggest Vaccine Candidate Variants and Epitopes. Microorganisms, 2022, 10, 1090.	1.6	2
2	Multidose Priming and Delayed Boosting Improve <i>Plasmodium falciparum</i> Sporozoite Vaccine Efficacy Against Heterologous <i>P. falciparum</i> Controlled Human Malaria Infection. Clinical Infectious Diseases, 2021, 73, e2424-e2435.	2.9	23
3	Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso. International Journal of Infectious Diseases, 2021, 102, 517-523.	1.5	20
4	Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing. Vaccine, 2021, 39, 1195-1200.	1.7	18
5	#63: Antibodies to Peptides Representing <i>Plasmodium falciparum</i> Circumsporozoite Protein Reflect Acquisition of Naturally Acquired Immunity in Malian Adults and Children. Journal of the Pediatric Infectious Diseases Society, 2021, 10, S10-S12.	0.6	O
6	Revisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial. Clinical Infectious Diseases, 2021, 73, 1058-1065.	2.9	8
7	Reply to Ramirez and Diaz-Quijano. Clinical Infectious Diseases, 2021, 73, 1551-1552.	2.9	O
8	Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. International Journal of Infectious Diseases, 2021, 108, 465-472.	1.5	14
9	Malian adults maintain serologic responses to virulent PfEMP1s amid seasonal patterns of fluctuation. Scientific Reports, 2021, 11, 14401.	1.6	2
10	Novel malaria vaccines. Human Vaccines and Immunotherapeutics, 2021, 17, 4549-4552.	1.4	7
11	Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome. Npj Vaccines, 2021, 6, 115.	2.9	2
12	Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. New England Journal of Medicine, 2021, 385, 1104-1115.	13.9	82
13	Epitope-Specific Antibody Responses to a <i>Plasmodium falciparum</i> Subunit Vaccine Target in a Malaria-Endemic Population. Journal of Infectious Diseases, 2021, 223, 1943-1947.	1.9	3
14	Successful Profiling of Plasmodium falciparum <i>var</i> Gene Expression in Clinical Samples via a Custom Capture Array. MSystems, 2021, 6, e0022621.	1.7	4
15	RTS,S/AS01 vaccine (Mosquirixâ,,¢): an overview. Human Vaccines and Immunotherapeutics, 2020, 16, 480-489.	1.4	232
16	Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/ASO2A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants. Vaccine, 2020, 38, 5700-5706.	1.7	5
17	High-dose Dexamethasone in a Child With Enteric Encephalopathy Caused by Salmonella enterica serovar Typhi. Pediatric Infectious Disease Journal, 2020, 39, e49-e51.	1.1	O
18	Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination. Scientific Reports, 2020, 10, 3952.	1.6	24

#	Article	IF	CITATIONS
19	Host and Parasite Transcriptomic Changes upon Successive Plasmodium falciparum Infections in Early Childhood. MSystems, 2020, 5, .	1.7	7
20	Dose-Dependent Infectivity of Aseptic, Purified, Cryopreserved Plasmodium falciparum 7G8 Sporozoites in Malaria-Naive Adults. Journal of Infectious Diseases, 2019, 220, 1962-1966.	1.9	17
21	Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL- $\hat{l}\pm$ tag. Malaria Journal, 2019, 18, 273.	0.8	6
22	Visceral Leishmaniasis in West Africa: Clinical Characteristics, Vectors, and Reservoirs. Journal of Parasitology Research, 2019, 2019, 1-8.	0.5	11
23	Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A. Malaria Journal, 2019, 18, 13.	0.8	8
24	Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi. Clinical Infectious Diseases, 2019, 68, S50-S58.	2.9	28
25	A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper. Clinical Infectious Diseases, 2019, 68, S59-S66.	2.9	9
26	Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure. MSphere, 2019, 4, .	1.3	23
27	Community Engagement Before Initiation of Typhoid Conjugate Vaccine Trial in Schools in Two Urban Townships in Blantyre, Malawi: Experience and Lessons. Clinical Infectious Diseases, 2019, 68, S146-S153.	2.9	13
28	Human challenge trials in vaccine development, Rockville, MD, USA, September 28–30, 2017. Biologicals, 2019, 61, 85-94.	0.5	29
29	The Controlled Human Malaria Infection Experience at the University of Maryland. American Journal of Tropical Medicine and Hygiene, 2019, 100, 556-565.	0.6	11
30	A targeted approach for routine viral load monitoring in Malawian adults on antiretroviral therapy. Tropical Medicine and International Health, 2018, 23, 526-532.	1.0	12
31	Children with cerebral malaria or severe malarial anaemia lack immunity to distinct variant surface antigen subsets. Scientific Reports, 2018, 8, 6281.	1.6	31
32	The Promise of a Malaria Vaccine—Are We Closer?. Annual Review of Microbiology, 2018, 72, 273-292.	2.9	47
33	Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2711-2716.	3.3	201
34	New var reconstruction algorithm exposes high var sequence diversity in a single geographic location in Mali. Genome Medicine, 2017, 9, 30.	3.6	13
35	Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine. PLoS ONE, 2017, 12, e0173294.	1.1	14
36	Frequent malaria illness episodes in two Malawian patients on antiretroviral therapy soon after stopping cotrimoxazole preventive therapy. Malawi Medical Journal, 2017, 29, 57.	0.2	2

3

#	Article	IF	CITATIONS
37	Spatio-Temporal Dynamics of Asymptomatic Malaria: Bridging the Gap Between Annual Malaria Resurgences in a Sahelian Environment. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1761-1769.	0.6	28
38	Plasmodium vivax Infections over 3 Years in Duffy Blood Group Negative Malians in Bandiagara, Mali. American Journal of Tropical Medicine and Hygiene, 2017, 97, 744-752.	0.6	52
39	TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial. Trials, 2016, 17, 322.	0.7	8
40	P-B9â€fTSCQ study. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 76.	0.9	0
41	Strain-specific Plasmodium falciparum multifunctional CD4+ T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate. Vaccine, 2016, 34, 2546-2555.	1.7	10
42	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine, 2016, 22, 614-623.	15.2	313
43	The Immunologic Complexity of Growing Up with Malariaâ€"Is Scientific Understanding Coming of Age?. Vaccine Journal, 2016, 23, 80-83.	3.2	5
44	Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1274-1284.	0.6	23
45	Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-NaĀ ⁻ ve Adults. PLoS ONE, 2015, 10, e0131571.	1.1	97
46	Seroreactivity to a Large Panel of Field-Derived Plasmodium falciparum Apical Membrane Antigen 1 and Merozoite Surface Protein 1 Variants Reflects Seasonal and Lifetime Acquired Responses to Malaria. American Journal of Tropical Medicine and Hygiene, 2015, 92, 9-12.	0.6	20
47	Differential Recognition of Terminal Extracellular Plasmodium falciparum VAR2CSA Domains by Sera from Multigravid, Malaria-Exposed Malian Women. American Journal of Tropical Medicine and Hygiene, 2015, 92, 1190-1194.	0.6	11
48	Hemoglobin C Trait Provides Protection From Clinical Falciparum Malaria in Malian Children. Journal of Infectious Diseases, 2015, 212, 1778-1786.	1.9	13
49	Vaccines Against Malaria. Clinical Infectious Diseases, 2015, 60, 930-936.	2.9	62
50	Controlled human malaria infections using aseptic, purified cryopreserved Plasmodium falciparum sporozoites administered by needle and syringe. Malaria Journal, 2014, 13, .	0.8	3
51	Stable malaria incidence despite scaling up control strategies in a malaria vaccine-testing site in Mali. Malaria Journal, 2014, 13, 374.	0.8	47
52	External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance. PLoS ONE, 2014, 9, e97398.	1.1	28
53	Spatio-temporal analysis of malaria within a transmission season in Bandiagara, Mali. Malaria Journal, 2013, 12, 82.	0.8	44
54	Common Indications for Pediatric Antibiotic Prophylaxis. Emergency Medicine Clinics of North America, 2013, 31, 875-894.	0.5	3

#	Article	IF	CITATIONS
55	Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine. Science, 2013, 341, 1359-1365.	6.0	686
56	Molecular Basis of Allele-Specific Efficacy of a Blood-Stage Malaria Vaccine: Vaccine Development Implications. Journal of Infectious Diseases, 2013, 207, 511-519.	1.9	66
57	Seroreactivity to Plasmodium falciparum Erythrocyte Membrane Protein 1 Intracellular Domain in Malaria-Exposed Children and Adults. Journal of Infectious Diseases, 2013, 208, 1514-1519.	1.9	20
58	Successful Human Infection with P. falciparum Using Three Aseptic Anopheles stephensi Mosquitoes: A New Model for Controlled Human Malaria Infection. PLoS ONE, 2013, 8, e68969.	1.1	26
59	Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial. PLoS ONE, 2013, 8, e79323.	1.1	38
60	Peritonitis and Technique Failure Caused by Roseomonas mucosa in an Adolescent Infected with HIV on Continuous Cycling Peritoneal Dialysis. Journal of Clinical Microbiology, 2012, 50, 3801-3804.	1.8	15
61	Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment. Malaria Journal, $2012,11,207.$	0.8	21
62	A Longitudinal Trial Comparing Chloroquine as Monotherapy or in Combination with Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria. PLoS ONE, 2012, 7, e42284.	1.1	30
63	Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8 ⁺ T Cell Immunity. Science, 2011, 334, 475-480.	6.0	475
64	A Field Trial to Assess a Blood-Stage Malaria Vaccine. New England Journal of Medicine, 2011, 365, 1004-1013.	13.9	311
65	Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial. PLoS ONE, 2010, 5, e13490.	1.1	42
66	Development of a metabolically active, non-replicating sporozoite vaccine to prevent <i>Plasmodium falciparum</i> malaria. Hum Vaccin, 2010, 6, 97-106.	2.4	258
67	Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial. PLoS ONE, 2010, 5, e9041.	1.1	54
68	MRSA with progression from otitis media and sphenoid sinusitis to clival osteomyelitis, pachymeningitis and abducens nerve palsy in an immunocompetent 10-year-old patient. International Journal of Pediatric Otorhinolaryngology, 2008, 72, 945-951.	0.4	37
69	Nonemergent Emergency Room Utilization for an Inner-City Pediatric Population. Pediatric Emergency Care, 2005, 21, 363-366.	0.5	26
70	Impact of a Population-Based Medical Curriculum on Specialty Choice. Journal of Health Care for the Poor and Underserved, 2001, 12, 261-271.	0.4	3